WO2006133286A3 - Treatment of tnf antagonist-resistant inflammatory disorders and related methods - Google Patents

Treatment of tnf antagonist-resistant inflammatory disorders and related methods Download PDF

Info

Publication number
WO2006133286A3
WO2006133286A3 PCT/US2006/022099 US2006022099W WO2006133286A3 WO 2006133286 A3 WO2006133286 A3 WO 2006133286A3 US 2006022099 W US2006022099 W US 2006022099W WO 2006133286 A3 WO2006133286 A3 WO 2006133286A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
treatment
patient
inflammatory disorders
related methods
Prior art date
Application number
PCT/US2006/022099
Other languages
French (fr)
Other versions
WO2006133286A2 (en
Inventor
Ilan Bank
Itamar Goldstein
Horin Shomron Ben
Leonard Chess
Koltakov Alexander
Original Assignee
Tel Hashomer Medical Res Infrastructure & Services Ltd
Ilan Bank
Itamar Goldstein
Horin Shomron Ben
Leonard Chess
Koltakov Alexander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Res Infrastructure & Services Ltd, Ilan Bank, Itamar Goldstein, Horin Shomron Ben, Leonard Chess, Koltakov Alexander filed Critical Tel Hashomer Medical Res Infrastructure & Services Ltd
Publication of WO2006133286A2 publication Critical patent/WO2006133286A2/en
Publication of WO2006133286A3 publication Critical patent/WO2006133286A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

In certain embodiments, the invention provides methods of treatment in which a VLA-I antagonist is administered to a patient who suffers from one or more inflammatory disorders, wherein: (1) the patient does not respond adequately to, or is unlikely to respond adequately to, TNFα antagonist therapy; or (2) the patient evidences tachyphylaxis and/or refractory effects during TNFα antagonist therapy; or (3) the VLA-I antagonist is administered as an adjuvant to TNFα antagonist monotherapy; and (4) wherein administration of the VLA-I antagonist is effective in treating the patient's inflammatory disorder(s).
PCT/US2006/022099 2005-06-07 2006-06-07 Treatment of tnf antagonist-resistant inflammatory disorders and related methods WO2006133286A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68821505P 2005-06-07 2005-06-07
US60/688,215 2005-06-07

Publications (2)

Publication Number Publication Date
WO2006133286A2 WO2006133286A2 (en) 2006-12-14
WO2006133286A3 true WO2006133286A3 (en) 2007-04-05

Family

ID=37496680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/022099 WO2006133286A2 (en) 2005-06-07 2006-06-07 Treatment of tnf antagonist-resistant inflammatory disorders and related methods

Country Status (1)

Country Link
WO (1) WO2006133286A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557768T3 (en) 1999-06-01 2016-01-28 Biogen Ma Inc. A blocking monoclonal antibody against VLA-1 and its use for the treatment of inflammatory disorders
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
PL2034830T3 (en) 2006-05-25 2015-04-30 Biogen Ma Inc Anti-vla-1 antibody for treating stroke
US20140017261A1 (en) * 2011-02-03 2014-01-16 Mark Totoritis Selection and treatment of subjects
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
AU2019299444A1 (en) * 2018-07-03 2021-01-14 Novartis Ag Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist
WO2021002887A1 (en) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146417A1 (en) * 1999-06-01 2002-10-10 Philip Gotwals Method for the treatment of inflammatory disorders
US20040081651A1 (en) * 2001-04-13 2004-04-29 Michael Karpusas Antibodies to vla-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146417A1 (en) * 1999-06-01 2002-10-10 Philip Gotwals Method for the treatment of inflammatory disorders
US20040081651A1 (en) * 2001-04-13 2004-04-29 Michael Karpusas Antibodies to vla-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEN-HORIN S ET AL: "The role of very late antigen-1 in immune-mediated inflammation", CLINICAL IMMUNOLOGY, ACADEMIC PRESS,, US, vol. 113, no. 2, November 2004 (2004-11-01), pages 119 - 129, XP004576813, ISSN: 1521-6616 *
BEN-HORIN SHOMRON ET AL: "Spontaneous ex vivo proliferation of synovial memory CD4+ T cells in auto-immune arthritis is oligoclonal, dependent upon VLA-1+ memory T cells, and inhibited by anti TNF alpha", FASEB JOURNAL, vol. 19, no. 4, Suppl. S, Part 1, March 2005 (2005-03-01), & EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A915, XP008072754, ISSN: 0892-6638 *
FIORUCCI STEFANO ET AL: "VLA-1 immunoneutralization protects against colon damage in a mouse model of colitis", GASTROENTEROLOGY, vol. 120, no. 5 Supplement 1, April 2001 (2001-04-01), & 102ND ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION AND DIGESTIVE DISEASE WEEK; ATLANTA, GEORGIA, USA; MAY 20-23, 2001, pages A.47, XP008072753, ISSN: 0016-5085 *
IANARO A ET AL: "Anti-very late antigen-1 monoclonal antibody modulates the development of secondary lesion and T-cell response in experimental arthritis", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 80, no. 1, 2000, pages 73 - 80, XP002974262, ISSN: 0023-6837 *
MARIETTE X: "Emerging biological therapies in rheumatoid arthritis", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 71, no. 6, November 2004 (2004-11-01), pages 470 - 474, XP004678683, ISSN: 1297-319X *
SU C ET AL: "Are there predictors of Remicade treatment success or failure?", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 57, no. 2, 6 January 2005 (2005-01-06), pages 237 - 245, XP004650707, ISSN: 0169-409X *

Also Published As

Publication number Publication date
WO2006133286A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2006133286A3 (en) Treatment of tnf antagonist-resistant inflammatory disorders and related methods
LUC00011I2 (en)
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2001062272A3 (en) Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
MX2009002893A (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates.
EP2087891A3 (en) Pharmaceutical compositions for treating lymphoma
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2005107793A3 (en) Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
WO2005009355A3 (en) Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2006086693A3 (en) Medical devices
WO2008051496A3 (en) Use of il-1 antagonists to treat gout and pseudogout
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2006044433A3 (en) Methods to treat or prevent viral-associated lymphoproliferative disorders
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2003022213A3 (en) Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
WO2009152415A3 (en) Reducing myocardial reperfusion injury by the combination therapy of protein kinase a activation and b1-adrenergic receptor blockade
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2002100317A3 (en) Targeted particles and methods of using the same
WO2008014386A3 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06784628

Country of ref document: EP

Kind code of ref document: A2